Outcome of sustained virological responders with histologically advanced chronic hepatitis C

Timothy R. Morgan, Marc G. Ghany, Hae Young Kim, Kristin K. Snow, Mitchell L. Shiffman, Jennifer L. De Santo, William M. Lee, Adrian M. Di Bisceglie, Herbert L. Bonkovsky, Jules L. Dienstag, Chihiro Morishima, Karen L. Lindsay, Anna S F Lok

Research output: Contribution to journalArticle

356 Citations (Scopus)

Abstract

Retrospective studies suggest that subjects with chronic hepatitis C and advanced fibrosis who achieve a sustained virological response (SVR) have a lower risk of hepatic decompensation and hepatocellular carcinoma (HCC). In this prospective analysis, we compared the rate of death from any cause or liver transplantation, and of liver-related morbidity and mortality, after antiviral therapy among patients who achieved SVR, virologic nonresponders (NR), and those with initial viral clearance but subsequent breakthrough or relapse (BT/R) in the HALT-C (Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis) Trial. Laboratory and/or clinical outcome data were available for 140 of the 180 patients who achieved SVR. Patients with nonresponse (NR; n = 309) or who experienced breakthrough or relapse (BT/R; n = 77) were evaluated every 3 months for 3.5 years and then every 6 months thereafter. Outcomes included death, liver-related death, liver transplantation, decompensated liver disease, and HCC. Median follow-up for the SVR, BT/R, and NR groups of patients was 86, 85, and 79 months, respectively. At 7.5 years, the adjusted cumulative rate of death/liver transplantation and of liver-related morbidity/mortality in the SVR group (2.2% and 2.7%, respectively) was significantly lower than that of the NR group (21.3% and 27.2%, P < 0.001 for both) but not the BT/R group (4.4% and 8.7%). The adjusted hazard ratio (HR) for time to death/liver transplantation (HR = 0.17, 95% confidence interval [CI] = 0.06-0.46) or development of liver-related morbidity/mortality (HR = 0.15, 95% CI = 0.06-0.38) or HCC (HR = 0.19, 95% CI = 0.04-0.80) was significant for SVR compared to NR. Laboratory tests related to liver disease severity improved following SVR. Conclusion: Patients with advanced chronic hepatitis C who achieved SVR had a marked reduction in death/liver transplantation, and in liver-related morbidity/mortality, although they remain at risk for HCC. (HEPATOLOGY 2010;52:833-844)

Original languageEnglish (US)
Pages (from-to)833-844
Number of pages12
JournalHepatology
Volume52
Issue number3
DOIs
StatePublished - Sep 2010

Fingerprint

Chronic Hepatitis C
Liver Transplantation
Mortality
Hepatocellular Carcinoma
Liver
Recurrence
Morbidity
Confidence Intervals
Antiviral Agents
Liver Diseases
Fibrosis
Hepatitis C
Cause of Death
Retrospective Studies
Therapeutics

ASJC Scopus subject areas

  • Hepatology
  • Medicine(all)

Cite this

Morgan, T. R., Ghany, M. G., Kim, H. Y., Snow, K. K., Shiffman, M. L., De Santo, J. L., ... Lok, A. S. F. (2010). Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology, 52(3), 833-844. https://doi.org/10.1002/hep.23744

Outcome of sustained virological responders with histologically advanced chronic hepatitis C. / Morgan, Timothy R.; Ghany, Marc G.; Kim, Hae Young; Snow, Kristin K.; Shiffman, Mitchell L.; De Santo, Jennifer L.; Lee, William M.; Di Bisceglie, Adrian M.; Bonkovsky, Herbert L.; Dienstag, Jules L.; Morishima, Chihiro; Lindsay, Karen L.; Lok, Anna S F.

In: Hepatology, Vol. 52, No. 3, 09.2010, p. 833-844.

Research output: Contribution to journalArticle

Morgan, TR, Ghany, MG, Kim, HY, Snow, KK, Shiffman, ML, De Santo, JL, Lee, WM, Di Bisceglie, AM, Bonkovsky, HL, Dienstag, JL, Morishima, C, Lindsay, KL & Lok, ASF 2010, 'Outcome of sustained virological responders with histologically advanced chronic hepatitis C', Hepatology, vol. 52, no. 3, pp. 833-844. https://doi.org/10.1002/hep.23744
Morgan TR, Ghany MG, Kim HY, Snow KK, Shiffman ML, De Santo JL et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology. 2010 Sep;52(3):833-844. https://doi.org/10.1002/hep.23744
Morgan, Timothy R. ; Ghany, Marc G. ; Kim, Hae Young ; Snow, Kristin K. ; Shiffman, Mitchell L. ; De Santo, Jennifer L. ; Lee, William M. ; Di Bisceglie, Adrian M. ; Bonkovsky, Herbert L. ; Dienstag, Jules L. ; Morishima, Chihiro ; Lindsay, Karen L. ; Lok, Anna S F. / Outcome of sustained virological responders with histologically advanced chronic hepatitis C. In: Hepatology. 2010 ; Vol. 52, No. 3. pp. 833-844.
@article{de8c7f208da048279647777160ec5177,
title = "Outcome of sustained virological responders with histologically advanced chronic hepatitis C",
abstract = "Retrospective studies suggest that subjects with chronic hepatitis C and advanced fibrosis who achieve a sustained virological response (SVR) have a lower risk of hepatic decompensation and hepatocellular carcinoma (HCC). In this prospective analysis, we compared the rate of death from any cause or liver transplantation, and of liver-related morbidity and mortality, after antiviral therapy among patients who achieved SVR, virologic nonresponders (NR), and those with initial viral clearance but subsequent breakthrough or relapse (BT/R) in the HALT-C (Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis) Trial. Laboratory and/or clinical outcome data were available for 140 of the 180 patients who achieved SVR. Patients with nonresponse (NR; n = 309) or who experienced breakthrough or relapse (BT/R; n = 77) were evaluated every 3 months for 3.5 years and then every 6 months thereafter. Outcomes included death, liver-related death, liver transplantation, decompensated liver disease, and HCC. Median follow-up for the SVR, BT/R, and NR groups of patients was 86, 85, and 79 months, respectively. At 7.5 years, the adjusted cumulative rate of death/liver transplantation and of liver-related morbidity/mortality in the SVR group (2.2{\%} and 2.7{\%}, respectively) was significantly lower than that of the NR group (21.3{\%} and 27.2{\%}, P < 0.001 for both) but not the BT/R group (4.4{\%} and 8.7{\%}). The adjusted hazard ratio (HR) for time to death/liver transplantation (HR = 0.17, 95{\%} confidence interval [CI] = 0.06-0.46) or development of liver-related morbidity/mortality (HR = 0.15, 95{\%} CI = 0.06-0.38) or HCC (HR = 0.19, 95{\%} CI = 0.04-0.80) was significant for SVR compared to NR. Laboratory tests related to liver disease severity improved following SVR. Conclusion: Patients with advanced chronic hepatitis C who achieved SVR had a marked reduction in death/liver transplantation, and in liver-related morbidity/mortality, although they remain at risk for HCC. (HEPATOLOGY 2010;52:833-844)",
author = "Morgan, {Timothy R.} and Ghany, {Marc G.} and Kim, {Hae Young} and Snow, {Kristin K.} and Shiffman, {Mitchell L.} and {De Santo}, {Jennifer L.} and Lee, {William M.} and {Di Bisceglie}, {Adrian M.} and Bonkovsky, {Herbert L.} and Dienstag, {Jules L.} and Chihiro Morishima and Lindsay, {Karen L.} and Lok, {Anna S F}",
year = "2010",
month = "9",
doi = "10.1002/hep.23744",
language = "English (US)",
volume = "52",
pages = "833--844",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - Outcome of sustained virological responders with histologically advanced chronic hepatitis C

AU - Morgan, Timothy R.

AU - Ghany, Marc G.

AU - Kim, Hae Young

AU - Snow, Kristin K.

AU - Shiffman, Mitchell L.

AU - De Santo, Jennifer L.

AU - Lee, William M.

AU - Di Bisceglie, Adrian M.

AU - Bonkovsky, Herbert L.

AU - Dienstag, Jules L.

AU - Morishima, Chihiro

AU - Lindsay, Karen L.

AU - Lok, Anna S F

PY - 2010/9

Y1 - 2010/9

N2 - Retrospective studies suggest that subjects with chronic hepatitis C and advanced fibrosis who achieve a sustained virological response (SVR) have a lower risk of hepatic decompensation and hepatocellular carcinoma (HCC). In this prospective analysis, we compared the rate of death from any cause or liver transplantation, and of liver-related morbidity and mortality, after antiviral therapy among patients who achieved SVR, virologic nonresponders (NR), and those with initial viral clearance but subsequent breakthrough or relapse (BT/R) in the HALT-C (Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis) Trial. Laboratory and/or clinical outcome data were available for 140 of the 180 patients who achieved SVR. Patients with nonresponse (NR; n = 309) or who experienced breakthrough or relapse (BT/R; n = 77) were evaluated every 3 months for 3.5 years and then every 6 months thereafter. Outcomes included death, liver-related death, liver transplantation, decompensated liver disease, and HCC. Median follow-up for the SVR, BT/R, and NR groups of patients was 86, 85, and 79 months, respectively. At 7.5 years, the adjusted cumulative rate of death/liver transplantation and of liver-related morbidity/mortality in the SVR group (2.2% and 2.7%, respectively) was significantly lower than that of the NR group (21.3% and 27.2%, P < 0.001 for both) but not the BT/R group (4.4% and 8.7%). The adjusted hazard ratio (HR) for time to death/liver transplantation (HR = 0.17, 95% confidence interval [CI] = 0.06-0.46) or development of liver-related morbidity/mortality (HR = 0.15, 95% CI = 0.06-0.38) or HCC (HR = 0.19, 95% CI = 0.04-0.80) was significant for SVR compared to NR. Laboratory tests related to liver disease severity improved following SVR. Conclusion: Patients with advanced chronic hepatitis C who achieved SVR had a marked reduction in death/liver transplantation, and in liver-related morbidity/mortality, although they remain at risk for HCC. (HEPATOLOGY 2010;52:833-844)

AB - Retrospective studies suggest that subjects with chronic hepatitis C and advanced fibrosis who achieve a sustained virological response (SVR) have a lower risk of hepatic decompensation and hepatocellular carcinoma (HCC). In this prospective analysis, we compared the rate of death from any cause or liver transplantation, and of liver-related morbidity and mortality, after antiviral therapy among patients who achieved SVR, virologic nonresponders (NR), and those with initial viral clearance but subsequent breakthrough or relapse (BT/R) in the HALT-C (Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis) Trial. Laboratory and/or clinical outcome data were available for 140 of the 180 patients who achieved SVR. Patients with nonresponse (NR; n = 309) or who experienced breakthrough or relapse (BT/R; n = 77) were evaluated every 3 months for 3.5 years and then every 6 months thereafter. Outcomes included death, liver-related death, liver transplantation, decompensated liver disease, and HCC. Median follow-up for the SVR, BT/R, and NR groups of patients was 86, 85, and 79 months, respectively. At 7.5 years, the adjusted cumulative rate of death/liver transplantation and of liver-related morbidity/mortality in the SVR group (2.2% and 2.7%, respectively) was significantly lower than that of the NR group (21.3% and 27.2%, P < 0.001 for both) but not the BT/R group (4.4% and 8.7%). The adjusted hazard ratio (HR) for time to death/liver transplantation (HR = 0.17, 95% confidence interval [CI] = 0.06-0.46) or development of liver-related morbidity/mortality (HR = 0.15, 95% CI = 0.06-0.38) or HCC (HR = 0.19, 95% CI = 0.04-0.80) was significant for SVR compared to NR. Laboratory tests related to liver disease severity improved following SVR. Conclusion: Patients with advanced chronic hepatitis C who achieved SVR had a marked reduction in death/liver transplantation, and in liver-related morbidity/mortality, although they remain at risk for HCC. (HEPATOLOGY 2010;52:833-844)

UR - http://www.scopus.com/inward/record.url?scp=77956635697&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956635697&partnerID=8YFLogxK

U2 - 10.1002/hep.23744

DO - 10.1002/hep.23744

M3 - Article

C2 - 20564351

AN - SCOPUS:77956635697

VL - 52

SP - 833

EP - 844

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 3

ER -